TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

NULYTELY-FLAVORED

POLYETHYLENE GLYCOL 3350 Osmotic Activity
Gastroenterology Approved 1991-04-22
1
Indication
--
Phase 3 Trials
34
Years on Market

Details

Status
Prescription
First Approved
1991-04-22
Routes
ORAL
Dosage Forms
FOR SOLUTION

NULYTELY-FLAVORED Approval History

Loading approval history...

What NULYTELY-FLAVORED Treats

1 indications

NULYTELY-FLAVORED is approved for 1 conditions since its original approval in 1991. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Constipation
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NULYTELY-FLAVORED FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Use • relieves occasional constipation (irregularity) • generally produces a bowel movement in 1 to 3 days

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.